NCT04355689已完成1 期
Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 49
- 试验地点
- 4
- 主要终点
- Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo
研究概览
简要总结
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
详细描述
This study will examine the safety and efficacy of oral NPI-001 Tablets as compared to oral placebo tablets for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Double-masked
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, age ≥18 years.
- •Able to comprehend and willing to sign an informed consent form (ICF) and to adhere to the study protocol.
- •Diagnosed with Usher syndrome.
- •EZ zone with width ≥500 microns, which includes the fovea in each eye at Visit 2, (Screen B).
- •Have at least 20 detectable points on the MAIA grid.
- •On stable dose of medications associated with other conditions for at least one month.
- •Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a bilateral oophorectomy, hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree to practice 2 acceptable methods of contraception throughout the course of the study and 4 weeks after the last visit. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, tubal ligation, or vasectomy.
排除标准
- •All edges of the EZ area in both eyes cannot be visualized at Visit 2 (Screen B).
- •Concurrent retinal pathologies that result in vision loss or inability to fixate, including but not limited to, choroideremia, retinal vein occlusion, and neovascular age-related macular degeneration.
- •Intraocular surgery within the last two months or capsulotomy within the last month.
- •History of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.
- •Unstable fixation during microperimetry in either eye at either screening or baseline visits.
- •Non-Ocular:
- •Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.
- •Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.
- •Liver or kidney disease, cystic fibrosis, asthma or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.
- •Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values > 1.5 X the upper limit of normal (ULN).
- •Platelet or hemoglobin values that are below the lower limit of normal at screening (subjects with normal hemoglobin and mean corpuscular volume below the lower limit of normal should have iron studies performed to ensure that they are iron replete before taking part in the study), or neutrophils or white cell count which is above the upper limit of normal.
- •Presence of more than + proteinuria on urinalysis at screening or (confirmed by abnormal albumin creatinine ratio).
- •Presence of hematuria on urinalysis at screening. (If hematuria is detected on urinalysis, then the specimen should be subjected to microscopy, and subject should be excluded if more than 10 X 106 red blood cells/L.) If the subject is a female in whom the hematuria may be due to menses, then the urinalysis can be repeated after a few days.
- •C-reactive protein (CRP) value above 10 mg/L.
- •Subject has a recent history of presence of gross blood in stools.
- •History of known sensitivity to N-acetylcysteine or similar thiol compounds.
- •History of hypersensitivity to any medication or food resulting in systemic symptoms.
- •History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.
- •Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.
- •Lactating women who are breast-feeding.
- •A potential participant lives in the same household as a current participant in this study.
- •Inability to provide blood samples, including difficulty with venous access.
- •Any reason, in the opinion of the Principal Investigator, the subject should not participate.
研究组 & 干预措施
NPI-001
Experimental
NPI-001 Tablet, 250 mg, BID
干预措施: NPI-001 (Drug)
Placebo
Placebo Comparator
Placebo Tablet, BID
干预措施: Placebo (Other)
结局指标
主要结局
Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo
时间窗: 24 months
Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placebo
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual DisabilityChronic Troublesome SialorrheaTraumatic Brain InjuryStrokeCerebral PalsyIntellectual DisabilityNCT02270736Merz Pharmaceuticals GmbH256
已完成
3 期
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute MigraineMigraine DisordersNCT00724815NuPathe Inc.530
已完成
1 期
A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.Healthy Volunteers - Liver DiseasesNCT06133270Novo Nordisk A/S51
已完成
2 期
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)Major Depressive DisorderNCT05203341Neurocrine Biosciences183
Unknown
3 期
Efficacy and Safety of Panlongqi Tablet in Patients With Knee OsteoarthritisKnee OsteoarthritisNCT03327012Guang'anmen Hospital of China Academy of Chinese Medical Sciences300